The ROI of Pharmacogenomics

August 2010
HealthLeaders Magazine;Aug2010, Vol. 13 Issue 8, p52
The article discusses how hospitals in the U.S. can benefit from pharmacogenomics tests. Although pharmacogenomics tests are expensive, they help in improving patient care as well as in avoiding unnecessary spending on medicine. One cost-effective pharmacogenomics test is the KRAS gene test. The KRAS test will determine if a patient has a specific mutation for the KRAS gene, which plays a role in colorectal cancer.


Related Articles

  • Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines. Vegter, Stefan; Boersma, Cornelis; Rozenbaum, Mark; Wilffert, Bob; Navis, GerJan; Postma, Maarten J. // PharmacoEconomics;2008, Vol. 26 Issue 7, p569 

    The fields of pharmacogenetics and pharmacogenomics have become important practical tools to progress goals in medical and pharmaceutical research and development. As more screening tests are being developed, with some already used in clinical practice, consideration of cost-effectiveness...

  • Pharmacogenetic testing before irinotecan likely to pay off?  // PharmacoEconomics & Outcomes News;10/17/2009, Issue 589, p6 

    The article discusses research on the cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 prior to irinotecan administration for metastatic colorectal cancer. It references a study by H. Gold Taffet, published in the September 2009 issue of the...

  • Pharmacogenomics of 5-Fluorouracil/Oxaliplatin in Colorectal Cancer. Gordon, Michael A.; Wu Zhang; Lenz, Heinz-Josef // Current Pharmacogenomics;Dec2006, Vol. 4 Issue 4, p277 

    Pharmacogenomic studies in the field of colorectal cancer have recently emerged as tools to benefit patients in receiving tailored chemotherapy and potentially improved therapeutic benefit. 5-fluorouracil/oxalplatin combination che-motherapy has been approved in the United States and Europe for...

  • Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Sie, A. S.; Mensenkamp, A. R.; Adang, E. M. M.; Ligtenberg, M. J. L.; Hoogerbrugge, N. // Annals of Oncology;Oct2014, Vol. 25 Issue 10, p2001 

    Recognising colorectal cancer (CRC) patients with Lynch syndrome (LS) can increase life expectancy for patients and relatives. By raising the age limit for CRC tumour genetic testing from 50 to 70 years, four times as many LS patients are detected, which is cost-effective when including family...

  • Routine histological sampling of doughnuts post oncologic anterior resection is not necessary. Ng, Celene; Lieske, Bettina; Tan, Ker-Kan // International Journal of Colorectal Disease;Jul2014, Vol. 29 Issue 7, p843 

    Background: A stapled end-to-end colo-rectal anastomosis is increasingly adopted following a proctectomy for various colorectal conditions. The ensuing doughnuts of colonic tissue created from the stapling device have been routinely sent for histological analysis. However, its efficacy remains...

  • Chemotherapy for advanced colorectal cancer. Michael, M; Zalcberg, J R // BMJ: British Medical Journal (International Edition);09/02/2000, Vol. 321 Issue 7260, p521 

    Editorial. Discusses the role of chemotherapy in improving the survival and quality of life of patients with advanced colorectal cancer. Comparison between chemotherapy and supportive care; Palliative benefits of chemotherapy among specific groups of patients; Cost effectiveness of such treatment.

  • Oral chemotherapy saves money in metastatic colorectal cancer.  // PharmacoEconomics & Outcomes News;9/6/2006, Issue 511, p8 

    The article discusses research being done on the clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. It references a study by S. E. Ward et al published in the July 2006 issue of the "British Journal of Cancer." The oral chemotherapy mentioned...

  • Capecitabine beats fluorouracil + folinic acid in colon cancer.  // PharmacoEconomics & Outcomes News;3/11/2006, Issue 498, p3 

    Presents information on a study on the cost effectiveness of adjuvant capecitabine in patients with Dukes stage C colorectal cancer, compared with fluorouracil plus folinic acid. Administration costs of the drugs; Average number of clinic visits per patient, associated with capecitabine;...

  • Lymph node sampling reduces costs in colon cancer.  // PharmacoEconomics & Outcomes News;3/11/2006, Issue 498, p7 

    Presents information on a study regarding the cost effectiveness of lymph node sampling in patients with stage II colorectal cancer. Treatment strategies employed in the study; Increase in quality-adjusted life-years, associated with improved lymph node sampling; Incremental cost-effectiveness...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics